EASL recommendations on treatment of hepatitis C: Final update of the series

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2020-11, Vol.73 (5), p.1170-1218
Main Authors: Pawlotsky, Jean-Michel, Negro, Francesco, Aghemo, Alessio, Berenguer, Marina, Dalgard, Olav, Dusheiko, Geoffrey, Marra, Fiona, Puoti, Massimo, Wedemeyer, Heiner
Format: Article
Language:English
Subjects:
Chronic infection
Hepatitis C
Interferon
Liver diseases
Patients
Public health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2020.08.018